CDT
Price
$0.51Alerts
Change
-$0.05 (-8.93%)
Updated
Nov 11 closing price
Capitalization
1.01M
One day until earnings call
Intraday BUY SELL Signals
CLRB
Price
$1.21Alerts
Change
-$0.01 (-0.82%)
Updated
Nov 11 closing price
Capitalization
11.82M
120 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CDT vs CLRB

CDT vs CLRB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CDT vs. CLRB commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDT is a Hold and CLRB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CDT with price predictions
Nov 10, 2026

CDT in -57.15% downward trend, sliding for three consecutive days on November 10, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CDT declined for three days, in 286 of 297 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for CDT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.010) is normal, around the industry mean (3.498). P/E Ratio (-0.001) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. CDT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for CLRB with price predictions
Nov 10, 2026

CLRB's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CLRB turned positive on October 23, 2026. Looking at past instances where CLRB's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLRB's RSI Indicator exited the oversold zone, 26 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 63 cases where CLRB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLRB as a result. In 71 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

Following a +11.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLRB advanced for three days, in 183 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

CLRB broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CLRB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.396) is normal, around the industry mean (3.498). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CLRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
CLRB: Fundamental Ratings
CLRB
OUTLOOK RATING
1..100
5
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
86
P/E GROWTH RATING
1..100
9
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CDTCLRB
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CDT: $0.56 vs. CLRB: $1.22)
Brand notoriety: CDT and CLRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDT: 102% vs. CLRB: 51%
Market capitalization -- CDT: $1.01M vs. CLRB: $11.82M
CDT [@Biotechnology] is valued at $1.01M. CLRB’s [@Biotechnology] market capitalization is $11.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDT’s FA Score shows that 1 FA rating(s) are green while CLRB’s FA Score has 1 green FA rating(s).

  • CDT’s FA Score: 1 green, 4 red.
  • CLRB’s FA Score: 1 green, 4 red.
According to our system of comparison, both CDT and CLRB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDT’s TA Score shows that 0 TA indicator(s) are bullish while CLRB’s TA Score has 5 bullish TA indicator(s).

  • CDT’s TA Score: 0 bullish, 2 bearish.
  • CLRB’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CLRB is a better buy in the short-term than CDT.

Price Growth

CDT (@Biotechnology) experienced а -58.11% price change this week, while CLRB (@Biotechnology) price change was -6.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

CDT is expected to report earnings on Nov 12, 2026.

CLRB is expected to report earnings on Mar 11, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CDT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDT has been loosely correlated with SLXN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CDT jumps, then SLXN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDT
1D Price
Change %
CDT100%
-33.19%
SLXN - CDT
44%
Loosely correlated
-11.22%
CMND - CDT
32%
Poorly correlated
-1.10%
PEPG - CDT
31%
Poorly correlated
+92.89%
ABEO - CDT
27%
Poorly correlated
-3.35%
CLRB - CDT
27%
Poorly correlated
-4.69%
More

CLRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLRB has been loosely correlated with QTTB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if CLRB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
-4.69%
QTTB - CLRB
62%
Loosely correlated
-0.11%
ADCT - CLRB
43%
Loosely correlated
-9.58%
RKTO - CLRB
42%
Loosely correlated
-3.87%
ANAB - CLRB
40%
Loosely correlated
+0.85%
VYGR - CLRB
38%
Loosely correlated
-8.29%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FSTR42.040.16
+0.38%
L.B. Foster Company
PODD148.06-1.75
-1.17%
Insulet Corp
HGTY16.94-0.28
-1.63%
Hagerty
WYY6.10-0.14
-2.24%
WidePoint Corp
IPDN1.08-0.06
-5.26%
Professional Diversity Network Inc